FEATURED COMPANIES

Provides analysis of over ten key marketed products and indentifies over 40 R&D candidates in preclinical to clinical stages of development.

The current market for hormonal contraceptives and infertility drugs is estimated at US$9.4bn, and is forecast to increase by 7% in annual revenues to US$10bn by 2014.

In this report, The Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018 - Future Therapies for Birth Control and Reproductive Health (2nd Edition) the reader will be introduced to an analysis of current product markets, research and development themes, and company activities within the field.

The report provides insights for product extension and reformulation, sales forecasts to 2018, and allows for assessments of the impact of late-stage pipeline drugs on the market. An overview of R&D programs within the field is also presented showing products from preclinical to premarket authorization phases of development. Therapy area forecasting to 2018 enables the reader to make key assumptions about future markets and prospects, and utilize the data for proprietary predictive market modelling.

Key findings of the report include- The
worldwide market for hormonal contraceptives is estimated at US$6.9bn in 2011, but is expected to decrease approximately 19.5% in annual revenues to US$5.5bn by 2018.- Drivers of growth for the hormonal contraception sector will be novel transdermal and intravaginal products that offer greater efficacy, lower dosing, and improved and longer control over menstruation.- Currently, there are over 40 pipeline candidates for female and male contraception.- The current worldwide market for infertility drugs is US$2.5bn; however the infertility therapy sector is underserved with drugs that are mainly focused on female infertility that induce ovulation for assisted conception programs.- Market leaders in the infertility sector include Merck Serono, Merck & Co., and Ferring with estimated revenues for their infertility products in 2011 at US$955m, US$625m and US$550m, respectively.- Drivers of growth will be through innovation to: reduce side effects associated with pituitary-gonadal drugs; enhance qualitative and quantitative aspects of ovulation and spermatogenesis; and improve overall fertilization and pregnancy-birth rates.- The male and female infertility R&D area is poorly served with only 15 pipeline candidates identified as potential clinical candidates.

Questions answered by this report include:- Which contraceptives and infertility drugs are the current and potential future market leaders- What impact new drug approvals will have on the reproductive medicine drug market- Which premarket drugs are identified as high-value products- Which companies are developing hormonal contraceptives and infertility drugs- Sales predictions to 2018 for leading contraceptives and infertility drugs- How will newcomers affect the product positioning of market leaders- What are niche market opportunities in reproductive medicine- What the future outlook holds for hormonal contraceptives and infertility pharmacotherapies- How companies are expanding the global reproductive medicine market through sophisticated reformulations and secondary indications for endocrinological and gynaecological disorders- Which molecules and compounds are main R&D clusters in reproductive medicine

4. Research and Development in Reproductive Health4.1 Female Oral Contraception4.1.1 Transdermal/Transmucosal Contraceptives4.1.2 Implantable/Injectable Contraceptives4.2 Male Contraception4.3 Contraception - Research and Development Overview4.4 Infertility Drugs in Research and Development4.4.1 Female Infertility4.4.2 Male Infertility6.3.2.1 Infertility - Research and Development Overview

But, post 2014, the market value will fall as generics come to market.

The market for female hormonal contraceptives is estimated to grow by 5% from $6.9bn in 2011 to $7.2bn by 2014, says a new report from URCH Publishing. However, after 2014, the market value will decline by over 19% to $5.5bn by 2018 as cheaper generics offset premium brands and innovative products.

The Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018 says that market leaders for female contraception include Bayer with annual revenues of $3bn, followed by Teva at $1.2bn, and Merck & Co. with $1bn in annual sales. High-revenue products include Bayer’s Yasmin/Yaz/Yasminelle franchise; Mirena, Merck & Co.’s NuvaRing; and Teva’s Ocella and Sprintec product lines, which collectively account for US$3.5bn in annual revenues.

Drivers of growth for the hormonal contraception sector will be novel transdermal and intravaginal products that offer greater efficacy, lower dosing, and improved and longer control over menstruation.

The report notes that “double-digit growth will be based on the introduction of sophisticated next-generation products along with prospects for male contraception, but this has yet to prove successful in long-term clinical trials.” Currently, there are over 40 pipeline candidates for female and male contraception.

The 67 page report analyses current product markets, research and development themes, and company activities within the field. The report evaluates sales trends and pharmacological innovation, and provides a detailed account of the newly approved and pipeline prospects that are anticipated to expand the market substantially over the next decade. Updates on novel drug development for male contraception and male infertility are detailed in addition to the commercial opportunities based on unmet needs.

The report provides insights for product extension and reformulation, sales forecasts to 2018, and allows for assessments of the impact of late-stage pipeline drugs on the market. An overview of R&D programs within the field is also presented showing products from preclinical to premarket authorization phases of development. Therapy area forecasting to 2018 enables the reader to make key assumptions about future markets and prospects, and utilize the data for proprietary predictive market modeling.

SUPPORT NEPAL

WHY CHOOSE RESEARCH AND MARKETS?

WORLD'S LARGEST SELECTION >Access to over 1,500,000 market research reports.

TRUSTED BY THE BEST >Over 400 of the Fortune 500 buy their research from us.

CUSTOMER FOCUSED >24 / 7 phone and email support.

SAFE & SECURE >Your payment details are protected by us.

KEEP UP TO DATE

ON ALL THE LATEST PRODUCTS

Enter your email address:

TESTIMONIALS

When I was placing my order I was unsure if my Visa card was authorised for the transaction and was unsure if my payment would be successful.
One minute after I inserted the VISA for payment I had a call from Claire from Research and Markets outlining there was a problem with my card and offering me different solutions to overcome that issue.
It was a great customer experience that clearly surprised me in a very positive way. I shared the experience with some of my colleagues at the office. thanks for your quick and efficient service!
Tiago BorgesCEOINOSAT SA